4CRF | Hydrolase | date | Feb 26, 2014 |
||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
title | Creating Novel F1 Inhibitors Through Fragment Based Lead Gen And Structure Aided Drug Design | ||||||||||||||
authors | J.Sandmark, L.Oster, O.Fjellstrom, S.Akkaya, H.G.Beisel, P.O.Erik K.Erixon, D.Gustafsson, U.Jurva, D.Kang, D.Karis, W.Knecht, V.Ner I.Nilsson, T.Olsson, A.Redzic, R.Roth, A.Tigerstrom | ||||||||||||||
compound | source | ||||||||||||||
Molecule: Coagulation Factor Xia Light Chain Chain: A Fragment: Catalytic Domain, Residues 388-625 Engineered: Yes Mutation: Yes |
Organism_scientific: Homo Sapiens Organism_common: Human Organism_taxid: 9606 Gene: F11 Expression_system: Pichia Pastoris Expression_system_taxid: 4922 | ||||||||||||||
symmetry | Space Group: I 2 3 |
| |||||||||||||
crystal cell |
| ||||||||||||||
method | X-Ray Diffraction | resolution | 2.30 Å | ||||||||||||
ligand | ALA, CL, GOL, R9B, SO4 | enzyme |
| ||||||||||||
Gene Ontology |
| ||||||||||||||
Primary reference | Creating Novel Activated Factor XI Inhibitors through Fragment Based Lead Generation and Structure Aided Drug Design., Fjellstrom O, Akkaya S, Beisel HG, Eriksson PO, Erixon K, Gustafsson D, Jurva U, Kang D, Karis D, Knecht W, Nerme V, Nilsson I, Olsson T, Redzic A, Roth R, Sandmark J, Tigerstrom A, Oster L, PLoS One. 2015 Jan 28;10(1):e0113705. doi: 10.1371/journal.pone.0113705., eCollection 2015. PMID:25629509 |
Data retrieval |
View 4CRF in 3D |
Visual 3D analysis of 4CRF |
Structure-derived information |
Sequence-derived information |
Other resources with information on 4CRF |
OCA© by Jaime Prilusky, 1996-2014,2022 Bioinformatics Unit Weizmann Institute of Science |